With a large patent portfolio and pending infringement case, Zecotek Photonics (Zecotek Photonics Stock Quote, Chart, News: TSXV:ZMS) is well positioned to benefit from growth in the lucrative positron emission tomography scanner market, says Zacks analyst Brian Marckx.
Marckx notes that Zecotek has a sizable patent portfolio that covers all its major products, including lasers, displays, LFS crystals, photo detectors, and other PET component technologies. This, he says, sets the junior apart as the only company to own all the key elements for a high end positron emission tomography (PET), a nuclear medical imaging technique that produces a three-dimensional image or picture of functional processes in the body.
The Zacks analyst says that while the carrying value of Zecotek’s patent portfolio is minimal, the “true tangible value” could be substantial, and that success in its current actions against giants Philips and Saint-Gobain could produce a result that dwarfs the company’s current market cap.
In a research update released October 3rd, Marckx initiated coverage of Zecotek with a BUY rating and a one-year price target of $4.00.
In February of last year, Zecotek filed a lawsuit in the United States District Court of Ohio against Philips and Saint-Gobain, alleging that Saint-Gobain’s LYSO crystals infringe Zecotek’s patent, and that Philips infringes by using those crystals in the PET scanners it sells. In August, the case completed its “Markman Hearing”, an important pretrial procedure that aims to determine the use of relevant key words in a patent claim.
Marckx says the courtroom is not the only place Zecotek is aiming to monetize its intellectual property. He notes that the company is developing and commercializing products built from their IP and has engaged leading IP firm involved in patent strategy and monetization, which includes patent purchasing, licensing, building and partnering.
In July, Zecotek announced it had received a $500,000 order for its patented Lutetium Fine Silicate (LFS) scintillation crystals from its strategic partner Hamamatsu Photonics, one of the world’s leading suppliers to the photonics industry.
At press time, shares of Zecotek were up 9.4% to $.93.
Zecotek is an annual sponsor of Cantech Letter.
The following disclosures relate to relationships between Zacks Investment Research (ZIR), Zacks & Company (ZCO ) and Zacks Small-Cap Research ( Zacks SCR ) and the issuers covered by the Zacks SCR analysts in the Small-Cap Universe.
ZIR or Zacks SCR Analysts do not hold or trade securities in the issuers which they cover. Each analyst has full discretion on the rating and price target based on their own due diligence. Analysts are paid in part based on the overall profitability of Zacks SCR. Such profitability is derived from a variety of sources and includes payments received from issuers of securities covered by Zacks SCR for non-investment banking services.
No part of analyst compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in any report or blog.
ZIR and Zacks SCR do not make a market in any security nor do they act as dealers in securities. Zacks SCR has never received compensation for investment banking services on the small-cap universe. Zacks SCR does not expect received compensation for investment banking services on the small-cap universe. Zacks SCR has received compensation for non-investment banking services on the small-cap universe, and expects to receive additional compensation for non-investment banking services on the small-cap universe, paid by issuers of securities covered by Zacks SCR. Non-investment banking services include investor relations services and software, financial database analysis, advertising services, brokerage services, advisory services, investment research, and investment management.
Additional information is available upon request. Zacks SCR reports are based on data obtained from sources we believe to be reliable, but is not guaranteed as to accuracy and does not purport to be complete. Because of individual objectives, the report should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed by Zacks SCR Analysts are subject to change.
Reports are not to be construed as an offer or the solicitation of an offer to buy or sell the securities herein mentioned.
ZCO and Zacks SCR are separate legal entities. ZCO is U.S. broker-dealer registered with the U.S. Securities and Exchange Commission and a member of the Financial Industry Regulatory Authority and the Securities Investor Protection Corp. This report is for your information only and is not an offer to sell, or a solicitation of an offer to buy, the securities or instruments through ZCO.
Zacks SCR uses the following rating system for the securities it covers. Buy/Outperform: The analyst expects that the subject company will outperform the broader U.S. equity market over the next one to two quarters. Hold/Neutral: The analyst expects that the company will perform in line with the broader U.S. equity market over the next one to two quarters. Sell/Underperform: The analyst expects the company will underperform the broader U.S. Equity market over the next one to two quarters.
The current distribution of Zacks Ratings is as follows on the 1020 companies covered: Buy/Outperform- 13.6%, Hold/Neutral- 79.7%, Sell/Underperform 5.8%. Data is as of midnight on the business day immediately prior to this publication.